Dividends & Buybacks ·
Alnylam authorizes $1.0B stock buyback program and announces departure of CCO Tolga Tanguler
ALNYAlnylam Pharmaceuticals, Inc.
The Board of Directors authorized a new repurchase program allowing the company to buy back up to $1.0 billion of its common stock through open market or privately negotiated transactions. The company anticipates spending approximately $500 million by the end of 2026, with the remainder executed during 2027. Separately, Executive Vice President and Chief Commercialization Officer Tolga Tanguler will depart in December 2026, pending a written separation agreement. Alnylam Pharmaceuticals is a biotechnology company focused on developing RNA interference therapeutics.